A personalized cancer vaccine developed by Moderna and Merck has generated widespread enthusiasm since the companies announced last week that it had succeeded in a late-stage trial. If regulators ultimately approve it, the treatment will be a triumph of immunology and cancer biology.
But it may also be a triumph of the algorithm.
The vaccine, intismeran autogene, would be the first approved medicine whose genetic instructions — that is, the individual letters of its mRNA — is determined by a computer.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
